Evidence map›Paper›PMID 24432238›Full record

ArticleMedical mycology case reports2013

Therapeutic drug monitoring in voriconazole-associated hyponatremia.

Ren-Ai Xu, Shuang-Li Zheng, Li-Li Xiao, Xue-Ding Cai, Xi-Xi Lai, Guan-Yang Lin, Lu-Feng Hu, Chun-Hong Zhang, Zhi-Sheng Xu, Xiu-Hua Zhang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Medical mycology case reports, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Study of Azole - Resistant andOpen access Macedonian journal of medical sciences · 2018
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Ren-Ai XuThe Second Affiliated Hospital of Wenzhou Medical College, Wenzhou 325000, China ; The First Affiliated Hospital of Wenzhou Medical College, Wenzhou 325000, China.
Shuang-Li ZhengThe First Affiliated Hospital of Wenzhou Medical College, Wenzhou 325000, China.
Li-Li XiaoThe First Affiliated Hospital of Wenzhou Medical College, Wenzhou 325000, China.
Xue-Ding CaiThe First Affiliated Hospital of Wenzhou Medical College, Wenzhou 325000, China.
Xi-Xi LaiThe First Affiliated Hospital of Wenzhou Medical College, Wenzhou 325000, China.
Guan-Yang LinThe Second Affiliated Hospital of Wenzhou Medical College, Wenzhou 325000, China.
Lu-Feng HuThe Second Affiliated Hospital of Wenzhou Medical College, Wenzhou 325000, China.
Chun-Hong ZhangThe Second Affiliated Hospital of Wenzhou Medical College, Wenzhou 325000, China.
Zhi-Sheng XuThe Second Affiliated Hospital of Wenzhou Medical College, Wenzhou 325000, China.
Xiu-Hua ZhangThe First Affiliated Hospital of Wenzhou Medical College, Wenzhou 325000, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Voriconazole is a second generation triazole antifungal agent and the first choice therapy for invasive aspergillosis (IA). Although voriconazole may be associated with many adverse events, hyponatremia has been rarely reported which potentially could result in death. Therapeutic drug monitoring (TDM) and individualization of therapy by measuring voriconazole plasma concentrations improved the efficacy and safety in patients. We report the effect of TDM to adjust voriconazole dosage in a voriconazole-related hyponatremia patient.

Indexed as

HyponatremiaInvasive pulmonary aspergillosisTherapeutic drug monitoringVoriconazole

Identifiers

PMID24432238
PMCPMC3885944

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.